CN Patent

CN114502537A — 突变型idh2抑制剂及其应用

Assigned to Betta Pharmaceuticals Co Ltd · Expires 2022-05-13 · 4y expired

What this patent protects

一种作为突变型异柠檬酸脱氢酶2(IDH2)抑制剂的化合物(如式I所示)及其制备方法、药物组合物。还涉及上述化合物或其药物组合物在治疗突变型IDH2介导的疾病中的用途。IDH2抑制剂能够抑制携带最常见IDH2突变体的细胞中2‑HG的生成，是一种低毒性作用且高效靶向抗肿瘤药物的理想靶标。

USPTO Abstract

一种作为突变型异柠檬酸脱氢酶2(IDH2)抑制剂的化合物(如式I所示)及其制备方法、药物组合物。还涉及上述化合物或其药物组合物在治疗突变型IDH2介导的疾病中的用途。IDH2抑制剂能够抑制携带最常见IDH2突变体的细胞中2‑HG的生成，是一种低毒性作用且高效靶向抗肿瘤药物的理想靶标。

Drugs covered by this patent

Patent Metadata

Patent number
CN114502537A
Jurisdiction
CN
Classification
—
Expires
2022-05-13
Drug substance claim
No
Drug product claim
No
Assignee
Betta Pharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.